Rezafungin, sold under the brand name Rezzayo (by Melinta Therapeutics), is a medication used for the treatment of invasive candidiasis. It is an echinocandin antifungal that acts as a fungal β-glucan synthase inhibitor.
Rezafungin, sold under the brand name Rezzayo (by Melinta Therapeutics), is a medication used for the treatment of invasive candidiasis. It is an echinocandin antifungal that acts as a fungal β-glucan synthase inhibitor.
Rezafungin was approved for medical use in the United States in March 2023, and in the European Union in December 2023.
Discovered by embedding cosine similarity (sentence-transformers MiniLM, 384-dim).